Last year I wrote an editorial for this journal in which I summarized the three primary objectives of the Pulmonary Vascular Research Institute (PVRI): to improve the care of patients all over the world who suffer from pulmonary vascular disease, to facilitate and accelerate research in the clinical and basic science of the disease, and to encourage the development of new therapies. As I approach the end of my term of office as president, it seems appropriate to consider the road traveled and the road ahead. We, the PVRI, began as a dedicated group of travelers led by Ghazwan Butrous as our inspirational managing director. Now we are a fully fledged professional organization with a permanent, stable infrastructure. We have approved and published the rules by which we govern ourselves (the "Regulations of the PVRI"), and we have an expanded worldwide membership, this superb journal led by two dedicated editors-in-chief, and an established program of annual international congresses and symposia. The congress held in Rome in January 2016 was the largest we have ever held. This coming year we are introducing a third annual conference that will be organized by, and run specifically for, the younger members of the PVRI, the Committee for Young Clinicians and Scientists. These young people are the most active members of the PVRI and are building strong links between colleagues in Europe, the Middle East, and Central Asia, which bodes well for the future of the PVRI.
meetings on high altitude. One will be held in Bishkek, in Central Asia, and will have significant scientific input, and the other will be held in Bolivia, focusing on medicine at high altitude. In the future it might be helpful to combine all this experience in a single meeting, preferably at sea level so that none of the participants has a headache and pulmonary hypertension! The PVRI can assist in all these endeavors by offering advice and expertise when appropriate, together with financial support. Many countries wish to develop clinical networks. This is very challenging, but several members of the PVRI have experience that can help others. Thus far the PVRI has not had the financial resources to develop a significant fellowship program. We need to give established clinicians working under difficult circumstances the opportunity to visit other centers for a limited period of time, while younger people will need a longer training period in centers of excellence. Hopefully, this will change next year with the promise of new monies.
Several developments have been hampered in the past year by the inadequacy of the current PVRI website. This is about to change, since a new PVRI website was launched in January 2016. Two initiatives are immediately feasible. First, we need to install an online consulting and discussion forum. This will offer help to all clinicians, particularly those working in isolated circumstances. Clinicians interact most avidly when discussing difficult cases, and this initiative will foster interaction, friendship, and networking. The second major initiative is a PVRI e-learning program that will be a modular course covering a wide range of topics from basic clinical "how to diagnose and treat" modules to erudite "current research" modules.
The PVRI is dedicated to curing pulmonary vascular disease and is fortunate to include leading research scientists in its membership. The recent formation of the Preclinical and Molecular Science Task Force will facilitate interaction among basic and clinical scientists. This group held its own very successful symposium in Rome, ahead of the scientific sessions of the annual congress, as did the Paediatric and Congenital Heart Disease Task Force. The members of the pediatric task force interact electronically throughout the year, and this approach should be fostered by other task forces. The annual congress is an ideal opportunity to exchange ideas and to plan activities for the coming year, but work should continue throughout the year if we are to make any real progress. All task forces, both regional and special interest, have the expertise to produce definitive review papers, and this can be exploited to good effect. The PVRI now supports meetings of the regional task forces throughout the year and will have to consider supporting special-interest task forces in a similar manner, financing face-to-face meetings to be held in addition to electronic forms of communication. This should Electronically published February 11, 2016. help accelerate scientific advances and help merge the interests of the developing and developed worlds to mutual advantage. Would it not be more appropriate to call our special-interest task forces "working groups"?
Bringing a drug to market is a difficult, long, and expensive business. We desperately need new therapies, rather than having to rely on different formulations and combinations of existing drugs. We need to target the determining causative signaling pathways that lie at the root of the problem. Despite greater understanding of the genetics and pathobiology of pulmonary vascular disease, selecting the most promising molecules and signaling pathway(s) to target therapeutically is difficult, and drug development is complex. Clinical trials are expensive and their outcome uncertain. The pharmaceutical industry has been understandably reluctant to invest in this field because the potential market is relatively small. The PVRI is anxious to strengthen relationships between basic scientists, clinicians, the pharmaceutical industry, and the regulatory authorities. We, the PVRI, now engage regularly with industry and with the regulatory authorities at the PVRI Annual Drug Development Symposium. The first symposium was held in 2014 in Washington to interact with the US Food and Drug Administration, and the second was held in London to involve the European Medicines Agency. This pattern will continue.
Perhaps surprisingly, the prevention of associated pulmonary vascular disease has received little attention. Prevention of schistosomiasis-associated pulmonary hypertension depends on public-health stratagems, usually in countries with limited financial resources. The PVRI could perhaps help their colleagues in these countries by supporting and advising them in pressing local governmental agencies to be more active. We are having more success in preventing the development of Eisenmenger syndrome by emphasizing the imperative of surgical correction of congenital heart disease in infancy. It is difficult for ministries of health in developing countries to realize that spending precious resources on infant cardiac surgery is a good investment until they appreciate that op-erating will not only relieve suffering but also remove a huge economic burden from the community and produce an economically useful citizen. Advocacy is a subtle art, but some members of the PVRI have experience that can help others.
The PVRI has always aimed to become the pivotal center of the pulmonary vascular disease world, to be the organization that people in medicine, research, the pharmaceutical industry, and government agencies think of when they need advice. In fact, we aim to become a "one-stop shop." We have an experienced, learned, worldwide membership and are gradually moving toward that goal. As we do so, we must be careful not to compromise the ethos that characterizes the PVRI: the spirit of friendship, warmth, and collaboration, the absence of hierarchy, the desire to promote the interests of the younger members of the community, and the need to help the less fortunate. We are building a tradition, a pattern of friendship and tolerance, and a calendar of events that the membership can anticipate and enjoy.
It has been a great privilege to be president of the PVRI. I am very grateful for the unfailing support given me by so many members and particularly by the Council and the Executive Committee of the PVRI. The PVRI has a great future and is just at the beginning of a long journey.
When you set out on the journey to Ithaka pray that the road be long, full of adventures, full of knowledge. . . . Ithaka gave you the wondrous voyage: without her, you would not have set out. (CP Cavafy: "Ithaka," in 154 Selected Poems, translated by Evangelos Sachperoglou; Athens: Tasos Vagenas, 2003) 
